Market Cap | 4.07M | P/E | - | EPS this Y | 97.40% | Ern Qtrly Grth | - |
Income | -13.04M | Forward P/E | -0.30 | EPS next Y | -300.00% | 50D Avg Chg | -37.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -83.00% |
Dividend | N/A | Price/Book | 0.11 | EPS next 5Y | - | 52W High Chg | -95.00% |
Recommedations | 1.50 | Quick Ratio | 2.76 | Shares Outstanding | 26.26M | 52W Low Chg | - |
Insider Own | 0.86% | ROA | -33.54% | Shares Float | 19.58M | Beta | -0.26 |
Inst Own | 26.37% | ROE | -142.88% | Shares Shorted/Prior | 73.44K/86.35K | Price | 0.56 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 270,170 | Target Price | 3.67 |
Oper. Margin | - | Earnings Date | May 7 | Volume | 93,777 | Change | -5.08% |
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
HC Wainwright & Co. | Buy | Mar 27, 24 |
HC Wainwright & Co. | Buy | Feb 9, 24 |
HC Wainwright & Co. | Buy | Nov 13, 23 |
HC Wainwright & Co. | Buy | Nov 6, 23 |
HC Wainwright & Co. | Buy | Aug 24, 23 |
HC Wainwright & Co. | Buy | Aug 14, 23 |
Maxim Group | Buy | Aug 9, 23 |
HC Wainwright & Co. | Buy | May 12, 23 |
HC Wainwright & Co. | Buy | Mar 24, 23 |